Viatris
CompanyUnited StatesFounded 202030,000 staff
Viatris develops 21 assets, the furthest approved (DILANTIN-125). Mostly small molecule and protein or enzyme acting on CACNA1C, CACNA1D and CACNA1S; based in the United States, founded in 2020.
- 21
- Assets
- Furthest stage
- Approved
- 462
- Trials
- 51
- Signals
Pipeline
21Approved
HMG-CoA reductase inhibitor lowering circulating low-density lipoprotein cholesterol levels.
Approved, Small molecule, HMGCR, angina pectoris, coronary artery disease
Approved, Small molecule, CACNA1G, CACNA1H, neuropathic pain, postherpetic neuralgia
18 more assets
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
73 assets, 4 trials
1 asset, 15 trials
1 asset, 7 trials
1 asset, 7 trials
1 asset, 6 trials
1 asset, 5 trials
13 trials
In the full profile
- Evidence behind the mechanisms11
- Trials486
- Deals1
- Signals20
- Similar companies6